New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 21, 2014
08:03 EDTCLSNCelsion announces regulatory cleraance to initiate Phase III study of Thermodox
Celsion announced it has received regulatory clearance to initiate its Phase III OPTIMA Study at clinical trial sites in Taiwan, Hong Kong, South Korea and Canada. The OPTIMA Study is the company's planned global pivotal, double-blind, placebo-controlled study evaluating ThermoDox, its proprietary heat-activated liposomal encapsulation of doxorubicin in combination with radiofrequency ablation, in primary liver cancer, also known as hepatocellular carcinoma. In addition, the company continues to advance its global regulatory strategy and has filed Clinical Trial Applications in the Philippines and Thailand, as well as a request for a Voluntary Harmonization Procedure in Europe, which provides for the assessment of multinational clinical trial applications across several European countries, including Germany, France and Spain. As previously reported, the company has submitted an Application for Accelerated Trial Approval to the China Food and Drug Administration. The Company also plans to expand its clinical site footprint in Europe and will meet with the European Medicines Agency during 2014 to discuss ThermoDox trial design and registrational strategy.
News For CLSN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 17, 2015
10:03 EDTCLSNHigh option volume stocks
High option volume stocks: EWC DF WPX CLSN TE CMA SWI CE VRSN USG
July 15, 2015
10:20 EDTCLSNCelsion rallies after firm sets $12 target while stock near $2 per share
Subscribe for More Information
10:01 EDTCLSNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:51 EDTCLSNCelsion initiated with a Buy at Maxim
Target $12.
July 14, 2015
19:05 EDTCLSNOn The Fly: Pre-market Movers
UP AFTER EARNINGS: CSX (CSX), up 3.5%. ALSO HIGHER: Receptos (RCPT), up 10.2% following deal to be acquired by Celgene (CELG)... Celgene is up 5.8% after announcing acquisition of Receptos... Celsion (CLSN), up 8.8% after being initiated with a Buy at BTIG... Aratana Therapeutics (PETX), up 10% after results of pivotal study of AT-003. DOWN AFTER EARNINGS: Peregrine (PPHM), down 3%... Yum! Brands (YUM), down marginally. ALSO LOWER: Allegheny Technologies (ATI), down 9.3% after providing second quarter EPS guidance... Mead Johnson (MJN), down 4.8% after reducing fiscal 2015 EPS guidance.
06:09 EDTCLSNCelsion initiated with a Buy at BTIG
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use